Recent advances in the clinical development of immune checkpoint blockade therapy

1.

K. Li, H. Tian, Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J. Drug Target 27, 244–256 (2019)

2.

D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011)CrossRefPubMed

3.

G.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, R.D. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002)CrossRefPubMed

4.

R.A. Lake, B.W. Robinson, Immunotherapy and chemotherapy--a practical partnership. Nat. Rev. Cancer. 5, 397–405 (2005)CrossRefPubMed

5.

I. Melero, G. Gaudernack, W. Gerritsen, C. Huber, G. Parmiani, S. Scholl, N. Thatcher, J. Wagstaff, C. Zielinski, I. Faulkner, H. Mellstedt, Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509–524 (2014)CrossRefPubMed

6.

M.M. Gubin, X. Zhang, H. Schuster, E. Caron, J.P. Ward, T. Noguchi, Y. Ivanova, J. Hundal, C.D. Arthur, W.J. Krebber, G.E. Mulder, M. Toebes, M.D. Vesely, S.S. Lam, A.J. Korman, J.P. Allison, G.J. Freeman, A.H. Sharpe, E.L. Pearce, T.N. Schumacher, R. Aebersold, H.G. Rammensee, C.J. Melief, E.R. Mardis, W.E. Gillanders, M.N. Artyomov, R.D. Schreiber, Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014)CrossRefPubMedPubMedCentral

7.

M.R. Zamani, S. Aslani, A. Salmaninejad, M.R. Javan, N. Rezaei, PD-1/PD-L and autoimmunity: A growing relationship. Cell. Immunol. 310, 27–41 (2016)CrossRefPubMed

8.

P. Sharma, K. Wagner, J.D. Wolchok, J.P. Allison, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer. 11, 805–812 (2011)CrossRefPubMedPubMedCentral

9.

A. Salmaninejad, S.F. Valilou, A.G. Shabgah, S. Aslani, M. Alimardani, A. Pasdar, A. Sahebkar, PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J. Cell. Physiol. (2019). https://doi.org/10.1002/jcp.28358

10.

P. Sharma, J.P. Allison, Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015)CrossRefPubMedPubMedCentral

11.

A. Hoos, Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 15, 235–247 (2016)CrossRefPubMed

12.

X. Zhang, J.-C.D. Schwartz, X. Guo, S. Bhatia, E. Cao, L. Chen, Z.-Y. Zhang, M.A. Edidin, S.G. Nathenson, S.C. Almo, Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20, 337–347 (2004)CrossRefPubMed

13.

A.H. Sharpe, E.J. Wherry, R. Ahmed, G.J. Freeman, The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8, 239–245 (2007)CrossRefPubMed

14.

L.M. Francisco, P.T. Sage, A.H. Sharpe, The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219–242 (2010)CrossRefPubMedPubMedCentral

15.

J. Chen, C.C. Jiang, L. Jin, X.D. Zhang, Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 27, 409–416 (2016)CrossRefPubMed

16.

M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, J.R. Wunderlich, M.E. Dudley, D.E. White, S.A. Rosenberg, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009)CrossRefPubMedPubMedCentral

17.

N. Yaghoubi, A. Soltani, K. Ghazvini, S.M. Hassanian, S.I. Hashemy, PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed. Pharmacother. 110, 312–318 (2018)CrossRefPubMed

18.

H. Nishimura, Y. Agata, A. Kawasaki, M. Sato, S. Imamura, N. Minato, H. Yagita, T. Nakano, T. Honjo, Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4–CD8–) thymocytes. Int. Immunol. 8, 773–780 (1996)CrossRefPubMed

19.

M. Mahmoudi, A. Rezaiemanesh, A. Salmaninejad, S. Harsini, S. Poursani, T. Bahrami, F. Tahghighi, V. Ziaee, N. Rezaei, PDCD1 single nucleotide genes polymorphisms confer susceptibility to juvenile-onset systemic lupus erythematosus. Autoimmunity 48, 488–493 (2015)CrossRefPubMed

20.

M.E. Keir, M.J. Butte, G.J. Freeman, A.H. Sharpe, PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008)CrossRefPubMed

21.

Y. Agata, A. Kawasaki, H. Nishimura, Y. Ishida, T. Tsubata, H. Yagita, T. Honjo, Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765–772 (1996)CrossRefPubMed

22.

T. Yamazaki, H. Akiba, H. Iwai, H. Matsuda, M. Aoki, Y. Tanno, T. Shin, H. Tsuchiya, D.M. Pardoll, K. Okumura, M. Azuma, H. Yagita, Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169, 5538–5545 (2002)CrossRefPubMed

23.

A.L. Kinter, E.J. Godbout, J.P. McNally, I. Sereti, G.A. Roby, M.A. O'Shea, A.S. Fauci, The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J. Immunol. 181, 6738–6746 (2008)CrossRefPubMed

24.

K.J. Oestreich, H. Yoon, R. Ahmed, J.M. Boss, NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 181, 4832–4839 (2008)CrossRefPubMed

25.

T. Watanabe, A. Bertoletti, T.A. Tanoto, PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J. Viral Hepat. 17, 453–458 (2010)CrossRefPubMed

26.

C.L. Day, D.E. Kaufmann, P. Kiepiela, J.A. Brown, E.S. Moodley, S. Reddy, E.W. Mackey, J.D. Miller, A.J. Leslie, C. DePierres, PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350–354 (2006)CrossRefPubMed

27.

M.J. Butte, M.E. Keir, T.B. Phamduy, A.H. Sharpe, G.J. Freeman, Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111–122 (2007)CrossRefPubMedPubMedCentral

28.

X. Zhong, J.R. Tumang, W. Gao, C. Bai, T.L. Rothstein, PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine binding. Eur. J. Immunol. 37, 2405–2410 (2007)CrossRefPubMed

29.

C. Blank, T.F. Gajewski, A. Mackensen, Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol. Immunother. 54, 307–314 (2005)CrossRefPubMed

30.

A.M. Paterson, K.E. Brown, M.E. Keir, V.K. Vanguri, L.V. Riella, A. Chandraker, M.H. Sayegh, B.R. Blazar, G.J. Freeman, A.H. Sharpe, The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J. Immunol. 187, 1097–1105 (2011)CrossRefPubMed

31.

J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, M. Nishimura, B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer. Res. 10, 5094–5100 (2004)CrossRefPubMed

32.

J.A. Brown, D.M. Dorfman, F.R. Ma, E.L. Sullivan, O. Munoz, C.R. Wood, E.A. Greenfield, G.J. Freeman, Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170, 1257–1266 (2003)CrossRefPubMed

33.

H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, V.A. Lennon, E. Celis, L. Chen, Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002)CrossRefPubMed

34.

R.H. Thompson, M.D. Gillett, J.C. Cheville, C.M. Lohse, H. Dong, W.S. Webster, K.G. Krejci, J.R. Lobo, S. Sengupta, L. Chen, H. Zincke, M.L. Blute, S.E. Strome, B.C. Leibovich, E.D. Kwon, Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl. Acad. Sci. U. S. A. 101, 17174–17179 (2004)CrossRefPubMedPubMedCentral

35.

J. Bai, Z. Gao, X. Li, L. Dong, W. Han, J. Nie, Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget 8, 110693 (2017)PubMedPubMedCentral

36.

N. Selenko-Gebauer, O. Majdic, A. Szekeres, G. Hofler, E. Guthann, U. Korthauer, G. Zlabinger, P. Steinberger, W.F. Pickl, H. Stockinger, W. Knapp, J. Stockl, B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol. 170, 3637–3644 (2003)CrossRefPubMed

37.

G.J. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L.J. Fitz, N. Malenkovich, T. Okazaki, M.C. Byrne, H.F. Horton, L. Fouser, L. Carter, V. Ling, M.R. Bowman, B.M. Carreno, M. Collins, C.R. Wood, T. Honjo, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000)CrossRefPubMedPubMedCentral

38.

Y. Latchman, C.R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A.J. Long, J.A. Brown, R. Nunes, E.A. Greenfield, K. Bourque, V.A. Boussiotis, L.L. Carter, B.M. Carreno, N. Malenkovich, H. Nishimura, T. Okazaki, T. Honjo, A.H. Sharpe, G.J. Freeman, PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261–268 (2001)CrossRefPubMed

39.

H. Dong, G. Zhu, K. Tamada, L. Chen, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365 (1999)CrossRefPubMed

40.

D.M. Kuang, Q. Zhao, C. Peng, J. Xu, J.P. Zhang, C. Wu, L. Zheng, Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206, 1327–1337 (2009)CrossRefPubMedPubMedCentral

41.

L. Zhang, T.F. Gajewski, J. Kline, PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114, 1545–1552 (2009)CrossRefPubMedPubMedCentral

42.

J.M. Chemnitz, R.V. Parry, K.E. Nichols, C.H. June, J.L. Riley, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945–954 (2004)CrossRefPubMed

43.

R.V. Parry, J.M. Chemnitz, K.A. Frauwirth, A.R. Lanfranco, I. Braunstein, S.V. Kobayashi, P.S. Linsley, C.B. Thompson, J.L. Riley, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543–9553 (2005)CrossRefPubMedPubMedCentral

44.

K.-A. Sheppard, L.J. Fitz, J.M. Lee, C. Benander, J.A. George, J. Wooters, Y. Qiu, J.M. Jussif, L.L. Carter, C.R. Wood, PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ. FEBS Lett. 574, 37–41 (2004)CrossRefPubMed

45.

A. Soltani, A. Bahreyni, N. Boroumand, M.K. Roshan, M. Khazaei, M. Ryzhikov, S. Soleimanpour, A. Avan, S.M. Hassanian, Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives. J. Cell. Physiol. 233, 4783–4790 (2018)CrossRefPubMed

46.

I.A. Mayer, C.L. Arteaga, The PI3K/AKT Pathway as a target for cancer treatment. Annu. Rev. Med. 67, 11–28 (2016)CrossRefPubMed

47.

N. Patsoukis, J. Brown, V. Petkova, F. Liu, L. Li and V.A. Boussiotis, Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 5, ra46 (2012)

48.

N. Patsoukis, L. Li, D. Sari, V. Petkova, V.A. Boussiotis, PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol. Cell. Biol. 33, 3091–3098 (2013)CrossRefPubMedPubMedCentral

49.

F. Vazquez, S. Ramaswamy, N. Nakamura, W.R. Sellers, Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 20, 5010–5018 (2000)CrossRefPubMedPubMedCentral

50.

J. Torres, R. Pulido, The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276, 993–998 (2001)PubMed

51.

T.G. Bivona, I. Perez De Castro, I.M. Ahearn, T.M. Grana, V.K. Chiu, P.J. Lockyer, P.J. Cullen, A. Pellicer, A.D. Cox, M.R. Philips, Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1. Nature 424, 694–698 (2003)CrossRefPubMed

52.

J.O. Ebinu, D.A. Bottorff, E.Y. Chan, S.L. Stang, R.J. Dunn, J.C. Stone, RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs. Science 280, 1082–1086 (1998)CrossRefPubMed

53.

J.O. Ebinu, S.L. Stang, C. Teixeira, D.A. Bottorff, J. Hooton, P.M. Blumberg, M. Barry, R.C. Bleakley, H.L. Ostergaard, J.C. Stone, RasGRP links T-cell receptor signaling to Ras. Blood 95, 3199–3203 (2000)PubMedCrossRef

54.

P.A. Ott, F.S. Hodi, C. Robert, CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer. Res. 19, 5300–5309 (2013)CrossRefPubMed

55.

D.M. Lussier, L. O'Neill, L.M. Nieves, M.S. McAfee, S.A. Holechek, A.W. Collins, P. Dickman, J. Jacobsen, P. Hingorani, J.N. Blattman, Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J. Immunother. 38, 96–106 (2015)CrossRefPubMedPubMedCentral

56.

R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, H.E. Kohrt, L. Horn, D.P. Lawrence, S. Rost, M. Leabman, Y. Xiao, A. Mokatrin, H. Koeppen, P.S. Hegde, I. Mellman, D.S. Chen, F.S. Hodi, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014)CrossRefPubMedPubMedCentral

57.

C. Robert, G.V. Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, J.C. Hassel, P. Rutkowski, C. McNeil, E. Kalinka-Warzocha, K.J. Savage, M.M. Hernberg, C. Lebbe, J. Charles, C. Mihalcioiu, V. Chiarion-Sileni, C. Mauch, F. Cognetti, A. Arance, H. Schmidt, D. Schadendorf, H. Gogas, L. Lundgren-Eriksson, C. Horak, B. Sharkey, I.M. Waxman, V. Atkinson, P.A. Ascierto, Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015)CrossRefPubMed

58.

O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, J.D. Wolchok, P. Hersey, R.W. Joseph, J.S. Weber, R. Dronca, T.C. Gangadhar, A. Patnaik, H. Zarour, A.M. Joshua, K. Gergich, J. Elassaiss-Schaap, A. Algazi, C. Mateus, P. Boasberg, P.C. Tumeh, B. Chmielowski, S.W. Ebbinghaus, X.N. Li, S.P. Kang, A. Ribas, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013)CrossRefPubMedPubMedCentral

59.

J. Brahmer, K.L. Reckamp, P. Baas, L. Crino, W.E. Eberhardt, E. Poddubskaya, S. Antonia, A. Pluzanski, E.E. Vokes, E. Holgado, D. Waterhouse, N. Ready, J. Gainor, O. Aren Frontera, L. Havel, M. Steins, M.C. Garassino, J.G. Aerts, M. Domine, L. Paz-Ares, M. Reck, C. Baudelet, C.T. Harbison, B. Lestini, D.R. Spigel, Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015)CrossRefPubMedPubMedCentral

60.

E.B. Garon, N.A. Rizvi, R. Hui, N. Leighl, A.S. Balmanoukian, J.P. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M.J. Ahn, E. Felip, J.S. Lee, M.D. Hellmann, O. Hamid, J.W. Goldman, J.C. Soria, M. Dolled-Filhart, R.Z. Rutledge, J. Zhang, J.K. Lunceford, R. Rangwala, G.M. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi, Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015)CrossRefPubMed

61.

T. Powles, J.P. Eder, G.D. Fine, F.S. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H.A. Burris, D.P. Petrylak, S.L. Teng, X. Shen, Z. Boyd, P.S. Hegde, D.S. Chen, N.J. Vogelzang, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014)CrossRefPubMed

62.

R.J. Motzer, B.I. Rini, D.F. McDermott, B.G. Redman, T.M. Kuzel, M.R. Harrison, U.N. Vaishampayan, H.A. Drabkin, S. George, T.F. Logan, K.A. Margolin, E.R. Plimack, A.M. Lambert, I.M. Waxman, H.J. Hammers, Nivolumab for metastatic renal cell carcinoma: Results of a randomized Phase II Trial. J. Clin. Oncol. 33, 1430–1437 (2015)CrossRefPubMed

63.

S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, W.H. Sharfman, J.R. Brahmer, D.P. Lawrence, M.B. Atkins, J.D. Powderly, P.D. Leming, E.J. Lipson, I. Puzanov, D.C. Smith, J.M. Taube, J.M. Wigginton, G.D. Kollia, A. Gupta, D.M. Pardoll, J.A. Sosman, F.S. Hodi, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020–1030 (2014)CrossRefPubMedPubMedCentral

64.

J. Naidoo, D.B. Page, B.T. Li, L.C. Connell, K. Schindler, M.E. Lacouture, M.A. Postow, J.D. Wolchok, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375–2391 (2015)PubMedPubMedCentral

65.

M.E. Valsecchi, Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 1270 (2015)CrossRefPubMed

66.

J.S. Weber, S.P. D’Angelo, D. Minor, F.S. Hodi, R. Gutzmer, B. Neyns, C. Hoeller, N.I. Khushalani, W.H. Miller Jr., C.D. Lao, G.P. Linette, L. Thomas, P. Lorigan, K.F. Grossmann, J.C. Hassel, M. Maio, M. Sznol, P.A. Ascierto, P. Mohr, B. Chmielowski, A. Bryce, I.M. Svane, J.J. Grob, A.M. Krackhardt, C. Horak, A. Lambert, A.S. Yang, J. Larkin, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384 (2015)CrossRefPubMed

67.

N.H. Segal, S.H.I. Ou, A.S. Balmanoukian, M.G. Fury, E. Massarelli, J.R. Brahmer, J. Weiss, P. Schoffski, S.J. Antonia, C. Massard, D.P. Zandberg, S. Khleif, X. Li, M. Rebelatto, K. Steele, P.B. Robbins, J.A. Blake-Haskins, M.O. Butler, Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J. Clin. Oncol. 33 (2015)

68.

S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, P.D. Leming, D.R. Spigel, S.J. Antonia, L. Horn, C.G. Drake, D.M. Pardoll, L. Chen, W.H. Sharfman, R.A. Anders, J.M. Taube, T.L. McMiller, H. Xu, A.J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G.D. Kollia, A. Gupta, J.M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012)CrossRefPubMedPubMedCentral

69.

D.S. Chen, B.A. Irving, F.S. Hodi, Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer. Res. 18, 6580–6587 (2012)CrossRefPubMed

70.

P. Sharma, S. Hu-Lieskovan, J.A. Wargo, A. Ribas, Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017)CrossRefPubMedPubMedCentral

71.

T.S. Nowicki, S. Hu-Lieskovan, A. Ribas, Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 24, 47–53 (2018)CrossRefPubMedPubMedCentral

72.

J. Polivka Jr., F. Janku, Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol. Ther. 142, 164–175 (2014)CrossRefPubMed

73.

H. Javid, A. Soltani, F. Mohammadi, S.I. Hashemy, Emerging roles of microRNAs in regulating the mTOR signaling pathway during tumorigenesis. J. Cell. Biochem. (2019). https://doi.org/10.1002/jcb.28401

74.

W. Peng, J.Q. Chen, C. Liu, S. Malu, C. Creasy, M.T. Tetzlaff, C. Xu, J.A. McKenzie, C. Zhang, X. Liang, L.J. Williams, W. Deng, G. Chen, R. Mbofung, A.J. Lazar, C.A. Torres-Cabala, Z.A. Cooper, P.L. Chen, T.N. Tieu, S. Spranger, X. Yu, C. Bernatchez, M.A. Forget, C. Haymaker, R. Amaria, J.L. McQuade, I.C. Glitza, T. Cascone, H.S. Li, L.N. Kwong, T.P. Heffernan, J. Hu, R.L. Bassett Jr., M.W. Bosenberg, S.E. Woodman, W.W. Overwijk, G. Lizee, J. Roszik, T.F. Gajewski, J.A. Wargo, J.E. Gershenwald, L. Radvanyi, M.A. Davies, P. Hwu, Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202–216 (2016)CrossRefPubMed

75.

S. Spranger, R. Bao, T.F. Gajewski, Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015)CrossRefPubMed

76.

R.F. Sweis, S. Spranger, R. Bao, G.P. Paner, W.M. Stadler, G. Steinberg, T.F. Gajewski, Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol. Res. 4, 563–568 (2016)CrossRefPubMedPubMedCentral

77.

S. Hu-Lieskovan, S. Mok, B. Homet Moreno, J. Tsoi, L. Robert, L. Goedert, E.M. Pinheiro, R.C. Koya, T.G. Graeber, B. Comin-Anduix, A. Ribas, Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med. 7, 279ra241 (2015)CrossRef

78.

W. Hugo, H. Shi, L. Sun, M. Piva, C. Song, X. Kong, G. Moriceau, A. Hong, K.B. Dahlman, D.B. Johnson, J.A. Sosman, A. Ribas, R.S. Lo, Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162, 1271–1285 (2015)CrossRefPubMedPubMedCentral

79.

L. Liu, P.A. Mayes, S. Eastman, H. Shi, S. Yadavilli, T. Zhang, J. Yang, L. Seestaller-Wehr, S.Y. Zhang, C. Hopson, L. Tsvetkov, J. Jing, S. Zhang, J. Smothers, A. Hoos, The BRAF and MEK inhibitors Dabrafenib and Trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin. Cancer Res. 21, 1639–1651 (2015)CrossRefPubMed

80.

P.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, A.N. West, M. Carmona, C. Kivork, E. Seja, G. Cherry, A.J. Gutierrez, T.R. Grogan, C. Mateus, G. Tomasic, J.A. Glaspy, R.O. Emerson, H. Robins, R.H. Pierce, D.A. Elashoff, C. Robert, A. Ribas, PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014)CrossRefPubMedPubMedCentral

81.

J.M. Zaretsky, A. Garcia-Diaz, D.S. Shin, H. Escuin-Ordinas, W. Hugo, S. Hu-Lieskovan, D.Y. Torrejon, G. Abril-Rodriguez, S. Sandoval, L. Barthly, J. Saco, B.H. Moreno, R. Mezzadra, B. Chmielowski, K. Ruchalski, I.P. Shintaku, P.J. Sanchez, C. Puig-Saus, G. Cherry, E. Seja, X. Kong, J. Pang, B. Berent-Maoz, B. Comin-Anduix, T.G. Graeber, P.C. Tumeh, T.N. Schumacher, R.S. Lo, A. Ribas, Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N. Engl. J. Med. 375, 819–829 (2016)CrossRefPubMedPubMedCentral

82.

J. Gao, L.Z. Shi, H. Zhao, J. Chen, L. Xiong, Q. He, T. Chen, J. Roszik, C. Bernatchez, S.E. Woodman, P.L. Chen, P. Hwu, J.P. Allison, A. Futreal, J.A. Wargo, P. Sharma, Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404 (2016)CrossRefPubMedPubMedCentral

83.

J.L. Benci, B. Xu, Y. Qiu, T.J. Wu, H. Dada, C. Twyman-Saint Victor, L. Cucolo, D.S.M. Lee, K.E. Pauken, A.C. Huang, T.C. Gangadhar, R.K. Amaravadi, L.M. Schuchter, M.D. Feldman, H. Ishwaran, R.H. Vonderheide, A. Maity, E.J. Wherry, A.J. Minn, Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554 (2016)CrossRefPubMedPubMedCentral

84.

L.C. Platanias, Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375–386 (2005)CrossRefPubMed

85.

A. Ribas, Adaptive Immune resistance: How cancer protects from immune attack. Cancer Discov. 5, 915–919 (2015)CrossRefPubMedPubMedCentral

86.

J.E. Darnell Jr., I.M. Kerr, G.R. Stark, Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415–1421 (1994)CrossRefPubMed

87.

M. Marzec, Q. Zhang, A. Goradia, P.N. Raghunath, X. Liu, M. Paessler, H.Y. Wang, M. Wysocka, M. Cheng, B.A. Ruggeri, M.A. Wasik, Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl. Acad. Sci. U. S. A. 105, 20852–20857 (2008)CrossRefPubMedPubMedCentral

88.

S. Alas, B. Bonavida, Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res. 9, 316–326 (2003)PubMed

89.

D.S. Shin, J.M. Zaretsky, H. Escuin-Ordinas, A. Garcia-Diaz, S. Hu-Lieskovan, A. Kalbasi, C.S. Grasso, W. Hugo, S. Sandoval, D.Y. Torrejon, N. Palaskas, G.A. Rodriguez, G. Parisi, A. Azhdam, B. Chmielowski, G. Cherry, E. Seja, B. Berent-Maoz, I.P. Shintaku, D.T. Le, D.M. Pardoll, L.A. Diaz Jr., P.C. Tumeh, T.G. Graeber, R.S. Lo, B. Comin-Anduix, A. Ribas, Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017)CrossRefPubMed

90.

M.H. Kaplan, A.L. Wurster, M.J. Grusby, A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells. J. Exp. Med. 188, 1191–1196 (1998)CrossRefPubMedPubMedCentral

91.

D.S. Shin, A. Ribas, The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr. Opin. Immunol. 33, 23–35 (2015)CrossRefPubMed

92.

C. Meyer, L. Cagnon, C.M. Costa-Nunes, P. Baumgaertner, N. Montandon, L. Leyvraz, O. Michielin, E. Romano, D.E. Speiser, Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247–257 (2014)CrossRefPubMed

93.

S.L. Highfill, Y. Cui, A.J. Giles, J.P. Smith, H. Zhang, E. Morse, R.N. Kaplan, C.L. Mackall, Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra267 (2014)CrossRef

94.

S.M. Steinberg, T.B. Shabaneh, P. Zhang, V. Martyanov, Z. Li, B.T. Malik, T.A. Wood, A. Boni, A. Molodtsov, C.V. Angeles, T.J. Curiel, M.L. Whitfield, M.J. Turk, Myeloid cells that impair immunotherapy are restored in melanomas with acquired resistance to BRAF inhibitors. Cancer Res. 77, 1599–1610 (2017)CrossRefPubMedPubMedCentral

95.

S. Sakaguchi, T. Yamaguchi, T. Nomura, M. Ono, Regulatory T cells and immune tolerance. Cell 133, 775–787 (2008)CrossRefPubMed

96.

K.G. Elpek, C. Lacelle, N.P. Singh, E.S. Yolcu, H. Shirwan, CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J. Immunol. 178, 6840–6848 (2007)CrossRefPubMed

97.

E. Bettelli, Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, H.L. Weiner, V.K. Kuchroo, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006)CrossRefPubMed

98.

F.A. Vargas, A.J.S. Furness, I. Solomon, K. Joshi, L. Mekkaoui, M.H. Lesko, E.M. Rota, R. Dahan, A. Georgiou, A. Sledzinska, A.B. Aissa, D. Franz, M.W. Sunderland, Y.N.S. Wong, J.Y. Henry, T. O'Brien, D. Nicol, B. Challacombe, S.A. Beers, S. Turajlic, M. Gore, J. Larkin, C. Swanton, K.A. Chester, M. Pule, J.V. Ravetch, T. Marafioti, K.S. Peggs, S.A. Quezada, Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46, 577–586 (2017)CrossRef

99.

N.A. Taylor, S.C. Vick, M.D. Iglesia, W.J. Brickey, B.R. Midkiff, K.P. McKinnon, S. Reisdorf, C.K. Anders, L.A. Carey, J.S. Parker, C.M. Perou, B.G. Vincent, J.S. Serody, Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J. Clin. Invest. 127, 3472–3483 (2017)CrossRefPubMedPubMedCentral

100.

J.J. Lebrun, The dual role of TGFbeta in human cancer: From tumor suppression to cancer metastasis. ISRN Mol. Biol. 2012, 381428 (2012)PubMedPubMedCentral

101.

C. Vanpouille-Box, J.M. Diamond, K.A. Pilones, J. Zavadil, J.S. Babb, S.C. Formenti, M.H. Barcellos-Hoff, S. Demaria, TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75, 2232–2242 (2015)CrossRefPubMedPubMedCentral

102.

Q. Yu, E. Sicinska, Y. Geng, M. Ahnstrom, A. Zagozdzon, Y. Kong, H. Gardner, H. Kiyokawa, L.N. Harris, O. Stal, P. Sicinski, Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23–32 (2006)CrossRefPubMed

103.

Y.J. Choi, X. Li, P. Hydbring, T. Sanda, J. Stefano, A.L. Christie, S. Signoretti, A.T. Look, A.L. Kung, H. von Boehmer, P. Sicinski, The requirement for cyclin D function in tumor maintenance. Cancer Cell 22, 438–451 (2012)CrossRefPubMedPubMedCentral

104.

J.L. Adams, J. Smothers, R. Srinivasan, A. Hoos, Big opportunities for small molecules in immuno-oncology. Nat. Rev. Drug Discov. 14, 603–622 (2015)CrossRefPubMed

105.

A.D. Wells, P.A. Morawski, New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation. Nat. Rev. Immunol. 14, 261–270 (2014)CrossRefPubMed

106.

S. Goel, M.J. DeCristo, A.C. Watt, H. BrinJones, J. Sceneay, B.B. Li, N. Khan, J.M. Ubellacker, S. Xie, O. Metzger-Filho, J. Hoog, M.J. Ellis, C.X. Ma, S. Ramm, I.E. Krop, E.P. Winer, T.M. Roberts, H.J. Kim, S.S. McAllister, J.J. Zhao, CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471–475 (2017)CrossRefPubMedPubMedCentral

107.

L. Jerby-Arnon, P. Shah, M.S. Cuoco, C. Rodman, M.J. Su, J.C. Melms, R. Leeson, A. Kanodia, S. Mei, J.R. Lin, S. Wang, B. Rabasha, D. Liu, G. Zhang, C. Margolais, O. Ashenberg, P.A. Ott, E.I. Buchbinder, R. Haq, F.S. Hodi, G.M. Boland, R.J. Sullivan, D.T. Frederick, B. Miao, T. Moll, K.T. Flaherty, M. Herlyn, R.W. Jenkins, R. Thummalapalli, M.S. Kowalczyk, I. Canadas, B. Schilling, A.N.R. Cartwright, A.M. Luoma, S. Malu, P. Hwu, C. Bernatchez, M.A. Forget, D.A. Barbie, A.K. Shalek, I. Tirosh, P.K. Sorger, K. Wucherpfennig, E.M. Van Allen, D. Schadendorf, B.E. Johnson, A. Rotem, O. Rozenblatt-Rosen, L.A. Garraway, C.H. Yoon, B. Izar, A. Regev, A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984–997 (2018)CrossRefPubMedPubMedCentral

108.

M.B. Atkins, R. Reiney, K.M. Sznol, D.F. McDermott, M. Lotem, J. Schachter, J.D. Wolchok, W.J. Urba, T. Kuzel, L.M. Schuchter, C.L. Slingluff, M.S. Ernstoff, J.W. Fay, P.A. Friedlander, T. Gajewski, H.M. Zarour, R. Rotem-Yehudar, J.A. Sosman, Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. J. Clin. Oncol. 32 (2014)

109.

R. Berger, R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. Koren-Michowitz, A. Shimoni, A. Nagler, Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer. Res. 14, 3044–3051 (2008)CrossRefPubMed

110.

J.R. Westin, F. Chu, M. Zhang, L.E. Fayad, L.W. Kwak, N. Fowler, J. Romaguera, F. Hagemeister, M. Fanale, F. Samaniego, L. Feng, V. Baladandayuthapani, Z. Wang, W. Ma, Y. Gao, M. Wallace, L.M. Vence, L. Radvanyi, T. Muzzafar, R. Rotem-Yehudar, R.E. Davis, S.S. Neelapu, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15, 69–77 (2014)CrossRefPubMed

111.

A. Patnaik, S.P. Kang, D. Rasco, K.P. Papadopoulos, J. Elassaiss-Schaap, M. Beeram, R. Drengler, C. Chen, L. Smith, G. Espino, K. Gergich, L. Delgado, A. Daud, J.A. Lindia, X.N. Li, R.H. Pierce, J.H. Yearley, D. Wu, O. Laterza, M. Lehnert, R. Iannone, A.W. Tolcher, Phase I study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in patients with advanced solid tumors. Clin. Cancer Res. 21, 4286–4293 (2015)CrossRefPubMed

112.

C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, R. Kefford, J.S. Weber, A.M. Joshua, W.J. Hwu, T.C. Gangadhar, A. Patnaik, R. Dronca, H. Zarour, R.W. Joseph, P. Boasberg, B. Chmielowski, C. Mateus, M.A. Postow, K. Gergich, J. Elassaiss-Schaap, X.N. Li, R. Iannone, S.W. Ebbinghaus, S.P. Kang, A. Daud, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384, 1109–1117 (2014)CrossRefPubMed

113.

A. Ribas, I. Puzanov, R. Dummer, D. Schadendorf, O. Hamid, C. Robert, F.S. Hodi, J. Schachter, A.C. Pavlick, K.D. Lewis, L.D. Cranmer, C.U. Blank, S.J. O'Day, P.A. Ascierto, A.K. Salama, K.A. Margolin, C. Loquai, T.K. Eigentler, T.C. Gangadhar, M.S. Carlino, S.S. Agarwala, S.J. Moschos, J.A. Sosman, S.M. Goldinger, R. Shapira-Frommer, R. Gonzalez, J.M. Kirkwood, J.D. Wolchok, A. Eggermont, X.N. Li, W. Zhou, A.M. Zernhelt, J. Lis, S. Ebbinghaus, S.P. Kang, A. Daud, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908–918 (2015)CrossRefPubMedPubMedCentral

114.

C. Robert, J. Schachter, G.V. Long, A. Arance, J.J. Grob, L. Mortier, A. Daud, M.S. Carlino, C. McNeil, M. Lotem, J. Larkin, P. Lorigan, B. Neyns, C.U. Blank, O. Hamid, C. Mateus, R. Shapira-Frommer, M. Kosh, H. Zhou, N. Ibrahim, S. Ebbinghaus, A. Ribas, Pembrolizumab versus Ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015)CrossRefPubMed

115.

R.S. Herbst, P. Baas, D.-W. Kim, E. Felip, J.L. Pérez-Gracia, J.-Y. Han, J. Molina, J.-H. Kim, C.D. Arvis, M.-J. Ahn, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet 387, 1540–1550 (2016)CrossRef

116.

J. Sul, G.M. Blumenthal, X. Jiang, K. He, P. Keegan, R. Pazdur, FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21, 643–650 (2016)CrossRefPubMedPubMedCentral

117.

E.R. Plimack, J. Bellmunt, S. Gupta, R. Berger, R.B. Montgomery, K. Heath, J. Juco, K. Emancipator, K. Pathiraja, J.K. Lunceford, R.F. Perini, P.H. O'Donnell, Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. J. Clin. Oncol. 33, 4502–4502 (2015)CrossRef

118.

A.V. Balar, D. Castellano, P.H. O'Donnell, P. Grivas, J. Vuky, T. Powles, E.R. Plimack, N.M. Hahn, R. de Wit, L. Pang, M.J. Savage, R.F. Perini, S.M. Keefe, D. Bajorin, J. Bellmunt, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017)CrossRefPubMed

119.

J. Bellmunt, R. de Wit, D.J. Vaughn, Y. Fradet, J.L. Lee, L. Fong, N.J. Vogelzang, M.A. Climent, D.P. Petrylak, T.K. Choueiri, A. Necchi, W. Gerritsen, H. Gurney, D.I. Quinn, S. Culine, C.N. Sternberg, Y. Mai, C.H. Poehlein, R.F. Perini, D.F. Bajorin, Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017)CrossRefPubMedPubMedCentral

120.

T.Y. Seiwert, R.I. Haddad, S. Gupta, R. Mehra, M. Tahara, R. Berger, S.-H. Lee, B. Burtness, D.T. Le, K. Heath, A. Blum, M. Dolled-Filhart, K. Emancipator, K. Pathiraja, J.D. Cheng, L.Q. Chow, Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. J. Clin. Oncol. 33, LBA6008–LBA6008 (2015)CrossRef

121.

J.R. Brahmer, C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, W.H. Sharfman, E. Stankevich, A. Pons, T.M. Salay, T.L. McMiller, M.M. Gilson, C. Wang, M. Selby, J.M. Taube, R. Anders, L. Chen, A.J. Korman, D.M. Pardoll, I. Lowy, S.L. Topalian, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167–3175 (2010)CrossRefPubMedPubMedCentral

122.

J.D. Wolchok, V. Chiarion-Sileni, R. Gonzalez, P. Rutkowski, J.J. Grob, C.L. Cowey, C.D. Lao, J. Wagstaff, D. Schadendorf, P.F. Ferrucci, M. Smylie, R. Dummer, A. Hill, D. Hogg, J. Haanen, M.S. Carlino, O. Bechter, M. Maio, I. Marquez-Rodas, M. Guidoboni, G. McArthur, C. Lebbe, P.A. Ascierto, G.V. Long, J. Cebon, J. Sosman, M.A. Postow, M.K. Callahan, D. Walker, L. Rollin, R. Bhore, F.S. Hodi, J. Larkin, Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017)CrossRefPubMedPubMedCentral

123.

J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J.J. Grob, C.L. Cowey, C.D. Lao, D. Schadendorf, R. Dummer, M. Smylie, P. Rutkowski, P.F. Ferrucci, A. Hill, J. Wagstaff, M.S. Carlino, J.B. Haanen, M. Maio, I. Marquez-Rodas, G.A. McArthur, P.A. Ascierto, G.V. Long, M.K. Callahan, M.A. Postow, K. Grossmann, M. Sznol, B. Dreno, L. Bastholt, A. Yang, L.M. Rollin, C. Horak, F.S. Hodi, J.D. Wolchok, Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015)CrossRefPubMedPubMedCentral

124.

S.N. Gettinger, M.D. Hellmann, F.A. Shepherd, S.J. Antonia, J.R. Brahmer, L.Q.M. Chow, J.W. Goldman, R.A. Juergens, H. Borghaei, N. Ready, D.E. Gerber, F.E. Nathan, Y. Shen, C. Harbison, N.A. Rizvi, First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. J. Clin. Oncol. 33, 8025–8025 (2015)CrossRef

125.

N.A. Rizvi, J. Mazieres, D. Planchard, T.E. Stinchcombe, G.K. Dy, S.J. Antonia, L. Horn, H. Lena, E. Minenza, B. Mennecier, G.A. Otterson, L.T. Campos, D.R. Gandara, B.P. Levy, S.G. Nair, G. Zalcman, J. Wolf, P.J. Souquet, E. Baldini, F. Cappuzzo, C. Chouaid, A. Dowlati, R. Sanborn, A. Lopez-Chavez, C. Grohe, R.M. Huber, C.T. Harbison, C. Baudelet, B.J. Lestini, S.S. Ramalingam, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257–265 (2015)CrossRefPubMedPubMedCentral

126.

H. Borghaei, L. Paz-Ares, L. Horn, D.R. Spigel, M. Steins, N.E. Ready, L.Q. Chow, E.E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhaufl, O. Arrieta, M.A. Burgio, J. Fayette, H. Lena, E. Poddubskaya, D.E. Gerber, S.N. Gettinger, C.M. Rudin, N. Rizvi, L. Crino, G.R. Blumenschein Jr., S.J. Antonia, C. Dorange, C.T. Harbison, F. Graf Finckenstein, J.R. Brahmer, Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015)CrossRefPubMedPubMedCentral

127.

S.J. Antonia, S.N. Gettinger, L.Q.M. Chow, R.A. Juergens, H. Borghaei, Y. Shen, C. Harbison, A.C. Chen, N. Ready, N.A. Rizvi, Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. J. Clin. Oncol. 32, 8023–8023 (2014)CrossRef

128.

R.J. Motzer, B. Escudier, D.F. McDermott, S. George, H.J. Hammers, S. Srinivas, S.S. Tykodi, J.A. Sosman, G. Procopio, E.R. Plimack, D. Castellano, T.K. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T.C. Gauler, T. Ueda, Y. Tomita, F.A. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J.S. Simon, L.A. Xu, I.M. Waxman, P. Sharma, Nivolumab versus Everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015)CrossRefPubMedPubMedCentral

129.

J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, A. Ueda, Y. Hosoe, S. Morita, A. Shimizu, T. Honjo, I. Konishi, Durable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumab. J. Clin. Oncol. 33, 5570–5570 (2015)CrossRef

130.

J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, A. Ueda, M. Kanai, Y. Mori, S. Matsumoto, T. Murayama, S. Chikuma, S. Morita, M. Yokode, A. Shimizu, T. Honjo, I. Konishi, Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 32, 5511–5511 (2014)CrossRef

131.

L. Festino, G. Botti, P. Lorigan, G.V. Masucci, J.D. Hipp, C.E. Horak, I. Melero, P.A. Ascierto, Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 expression a biomarker for patient selection? Drugs 76, 925–945 (2016)CrossRefPubMed

132.

R.S. Herbst, M.S. Gordon, G.D. Fine, J.A. Sosman, J.-C. Soria, O. Hamid, J.D. Powderly, H.A. Burris, A. Mokatrin, M. Kowanetz, M. Leabman, M. Anderson, D.S. Chen, F.S. Hodi, A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J. Clin. Oncol. 31, 3000–3000 (2013)

133.

H. Mizugaki, N. Yamamoto, H. Murakami, H. Kenmotsu, Y. Fujiwara, Y. Ishida, T. Kawakami, T. Takahashi, Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest. New Drugs 34, 596–603 (2016)CrossRefPubMedPubMedCentral

134.

L. Horn, D.R. Spigel, S.N. Gettinger, S.J. Antonia, M.S. Gordon, R.S. Herbst, L.V. Sequist, C. Chappey, M. Kowanetz, A. Sandler, J.C. Soria, Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. J. Clin. Oncol. 33, 8029–8029 (2015)CrossRef

135.

S. Peters, S. Gettinger, M.L. Johnson, P.A. Janne, M.C. Garassino, D. Christoph, C.K. Toh, N.A. Rizvi, J.E. Chaft, E.C. Costa, J.D. Patel, L.Q.M. Chow, M. Koczywas, C. Ho, M. Fruh, M. van den Heuvel, J. Rothenstein, M. Reck, L. Paz-Ares, F.A. Shepherd, T. Kurata, Z. Li, J. Qiu, M. Kowanetz, S. Mocci, G. Shankar, A. Sandler, E. Felip, Phase II trial of Atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J. Clin. Oncol. 35, 2781–2789 (2017)CrossRefPubMedPubMedCentral

136.

J.E. Rosenberg, J. Hoffman-Censits, T. Powles, M.S. van der Heijden, A.V. Balar, A. Necchi, N. Dawson, P.H. O'Donnell, A. Balmanoukian, Y. Loriot, S. Srinivas, M.M. Retz, P. Grivas, R.W. Joseph, M.D. Galsky, M.T. Fleming, D.P. Petrylak, J.L. Perez-Gracia, H.A. Burris, D. Castellano, C. Canil, J. Bellmunt, D. Bajorin, D. Nickles, R. Bourgon, G.M. Frampton, N. Cui, S. Mariathasan, O. Abidoye, G.D. Fine, R. Dreicer, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909–1920 (2016)CrossRefPubMedPubMedCentral

137.

A.V. Balar, M.D. Galsky, J.E. Rosenberg, T. Powles, D.P. Petrylak, J. Bellmunt, Y. Loriot, A. Necchi, J. Hoffman-Censits, J.L. Perez-Gracia, N.A. Dawson, M.S. van der Heijden, R. Dreicer, S. Srinivas, M.M. Retz, R.W. Joseph, A. Drakaki, U.N. Vaishampayan, S.S. Sridhar, D.I. Quinn, I. Duran, D.R. Shaffer, B.J. Eigl, P.D. Grivas, E.Y. Yu, S. Li, E.E. Kadel 3rd, Z. Boyd, R. Bourgon, P.S. Hegde, S. Mariathasan, A. Thastrom, O.O. Abidoye, G.D. Fine, D.F. Bajorin, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67–76 (2017)CrossRefPubMed

138.

D.P. Petrylak, T. Powles, J. Bellmunt, F. Braiteh, Y. Loriot, R. Morales-Barrera, H.A. Burris, J.W. Kim, B. Ding, C. Kaiser, M. Fasso, C. O'Hear, N.J. Vogelzang, Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: Long-term outcomes from a Phase 1 study. JAMA Oncol. 4, 537–544 (2018)CrossRefPubMedPubMedCentral

139.

O. Hamid, J.A. Sosman, D.P. Lawrence, R.J. Sullivan, N. Ibrahim, H.M. Kluger, P.D. Boasberg, K. Flaherty, P. Hwu, M. Ballinger, A. Mokatrin, M. Kowanetz, D.S. Chen, F.S. Hodi, Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J. Clin. Oncol. 31, 9010–9010 (2013)

140.

D.F. McDermott, J.A. Sosman, M. Sznol, C. Massard, M.S. Gordon, O. Hamid, J.D. Powderly, J.R. Infante, M. Fassò, Y.V. Wang, Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J. Clin. Oncol. 34, 833–842 (2016)CrossRefPubMed

141.

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste, J. Mazieres, K. Park, D. Smith, A. Artal-Cortes, C. Lewanski, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 387, 1837–1846 (2016)CrossRef

142.

M.A. Socinski, R.M. Jotte, F. Cappuzzo, F. Orlandi, D. Stroyakovskiy, N. Nogami, D. Rodriguez-Abreu, D. Moro-Sibilot, C.A. Thomas, F. Barlesi, G. Finley, C. Kelsch, A. Lee, S. Coleman, Y. Deng, Y. Shen, M. Kowanetz, A. Lopez-Chavez, A. Sandler, M. Reck, Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018)CrossRefPubMed

143.

S.S. Tykodi, J.R. Brahmer, W.J. Hwu, L.Q. Chow, S.L. Topalian, P. Hwu, K. Odunsi, L.H. Camacho, J.S. Kauh, H.C. Pitot, O. Hamid, D.M. Pardoll, S. Agrawal, S. Parker, S. Goldberg, A.K. Gupta, J. Wigginton, PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. J. Clin. Oncol. 30, 2510–2510 (2012)

144.

C.R. Heery, G.H.O. Coyne, R.A. Madan, J. Schlom, A. von Heydebreck, J.M. Cuillerot, H. Sabzevari, J.L. Gulley, Phase I open-label, multiple ascending dose trial of MSB0010718C, an anti-PD-L1 monoclonal antibody, in advanced solid malignancies. J. Clin. Oncol. 32, 3064–3064 (2014)CrossRef

145.

M.L. Disis, M.R. Patel, S. Pant, E.P. Hamilton, A.C. Lockhart, K. Kelly, J.T. Beck, M.S. Gordon, G.J. Weiss, M.H. Taylor, J. Chaves, A.C. Mita, K.M. Chin, A.V. Heydebreck, J.-M. Cuillerot, J.L. Gulley, Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. J. Clin. Oncol. 34, 5533–5533 (2016)CrossRef

146.

A.B. Apolo, J.A. Ellerton, J.R. Infante, M. Agrawal, M.S. Gordon, R. Aljumaily, C.D. Britten, L.Y. Dirix, K.W. Lee, M.H. Taylor, P. Schoffski, D. Wang, A. Ravaud, A. Gelb, J. Xiong, G. Rosen, M.R. Patel, Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study. J. Clin. Oncol. 35, 4528–4528 (2017)CrossRef

147.

J.L. Gulley, D. Spigel, K. Kelly, J.C. Chandler, A. Rajan, R. Hassan, D.J.L. Wong, J. Leach, W.J. Edenfield, D. Wang, N. Vrindavanam, G.J. Weiss, J.S. Gurtler, H.J. Grote, A. von Heydebreck, K.M. Chin, N. Iannotti, Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J. Clin. Oncol. 33, 8034–8034 (2015)CrossRef

148.

J. Lutzky, S.J. Antonia, A. Blake-Haskins, X. Li, P.B. Robbins, A.M. Shalabi, J. Vasselli, R.A. Ibrahim, S. Khleif, N.H. Segal, A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors. J. Clin. Oncol. 32, 3001–3001 (2014)CrossRef

149.

N.A. Rizvi, J.R. Brahmer, S.H.I. Ou, N.H. Segal, S. Khleif, W.J. Hwu, M. Gutierrez, P. Schoffski, O. Hamid, J. Weiss, J. Lutzky, M. Maio, J.J. Nemunaitis, D. Jaeger, A.S. Balmanoukian, M. Rebelatto, K. Steele, X. Li, J.A. Blake-Haskins, S.J. Antonia, Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33, 8032–8032 (2015)CrossRef

150.

S.J. Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, T. Yokoi, A. Chiappori, K.H. Lee, M. de Wit, B.C. Cho, M. Bourhaba, X. Quantin, T. Tokito, T. Mekhail, D. Planchard, Y.C. Kim, C.S. Karapetis, S. Hiret, G. Ostoros, K. Kubota, J.E. Gray, L. Paz-Ares, J. de Castro Carpeno, C. Wadsworth, G. Melillo, H. Jiang, Y. Huang, P.A. Dennis, M. Ozguroglu, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017)CrossRefPubMed

151.

N.M. Hahn, T. Powles, C. Massard, H.T. Arkenau, T.W. Friedlander, C.J. Holmes, J.L. Lee, M. Ong, S.S. Sridhar, N.J. Vogelzang, M.N. Fishman, J. Zhang, S. Srinivas, J. Parikh, J. Antal, X. Jin, Y. Ben, A.K. Gupta, P.H. O'Donnell, Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC). J. Clin. Oncol. 35, 4525–4525 (2017)CrossRef

Springer Medizin

Recent advances in the clinical development of immune checkpoint blockade therapy

Abstract

Background

Conclusions

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Springer Medizin

Abstract

Background

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Interplay between HSF1 and p53 signaling pathways in cancer initiation and progression: non-oncogene and oncogene addiction

Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy

Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial

Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells

Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells

The role of TNF-α in chordoma progression and inflammatory pathways

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien